预约演示
更新于：2025-02-08
Ciclesonide
环索奈德
更新于：2025-02-08
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2004-02-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS号126544-47-6 |
关联
108
项与 环索奈德 相关的临床试验CTR20244577
环索奈德吸入气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
CTR20233942
环索奈德气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
EUCTR2020-002208-37-DK
The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19. - CIMMCov
100 项与 环索奈德 相关的临床结果
登录后查看更多信息
100 项与 环索奈德 相关的转化医学
登录后查看更多信息
100 项与 环索奈德 相关的专利（医药）
登录后查看更多信息
750
项与 环索奈德 相关的文献（医药）2025-02-01THORAX
Inhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease
Article
作者: Ioannides, Anne E ; Kallis, Constantinos ; Whittaker, Hannah R ; Quint, Jennifer K
Background:
Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated.
Objectives:
To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared with long-acting bronchodilators; and (2) whether drug class, incident usership or patient cardiovascular history influenced the ICS-MACE relationship.
Methods:
We conducted a cohort study including patients with COPD in England, using Clinical Practice Research Datalink Aurum data, linked with Hospital Episode Statistics and Office of National Statistics death data, between 1 January 2010 and 31 December 2019. We implemented Cox proportional hazard regressions, adjusting for time interactions or using propensity score-adjusted models, as necessary. Our exposures included prescriptions of any ICS (vs any long-acting bronchodilators) and triple therapy (vs combination long-acting bronchodilators), determined during the year prior to follow-up. The outcomes of interest were MACE collectively and individual MACE subtypes.
Measurements and main results:
Among 113 353 people with COPD (mean age 67.9 years old, 53.3% male), ICS prescription was not associated with MACE (adjusted HR (95% CI)=0.98 (0.95, 1.02), p=0.41) but was associated with reduced HF, specifically, until year 6 of follow-up (average adjusted HR (95% CI)=0.91 (0.86, 0.96), p<0.001). HF reduction was driven by the ICS group containing mometasone furoate, beclomethasone, budesonide or ciclesonide (HR (95% CI)=0.89 (0.84, 0.94), p<0.001). Incident ICS use was associated with increased ACS (HR (95% CI)=1.27 (1.09, 1.47), p<0.001) but was not sustained beyond incident use. There was no association between triple therapy and MACE. Results did not differ by cardiovascular history.
Conclusions:
ICS did not reduce MACE, except HF, likely by reducing misclassified COPD exacerbations.
2025-01-15The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
Prenatal medication use in a prospective pregnancy cohort by pre-pregnancy obesity status
Article
作者: Smarr, Melissa M. ; Wing, Deborah A. ; Yeung, Edwina H. ; Vafai, Yassaman ; Gerlanc, Nicole ; Skupski, Daniel ; Sciscione, Anthony ; Ranzini, Angela C. ; Newman, Roger B. ; Grewal, Jagteshwar ; Grobman, William A. ; Sundaram, Rajeshwari ; Chien, Edward K. ; Grantz, Katherine L. ; Hinkle, Stefanie N. ; Zhang, Cuilin
BACKGROUND:
The association between obesity (body mass index (BMI) ≥ 30 kg/m2) and pattern of medication use during pregnancy in the United States is not well-studied. Higher pre-pregnancy BMI may be associated with increases or decreases in medication use across pregnancy as symptoms (e.g. reflux) or comorbidities (e.g. gestational diabetes) requiring treatment that may be associated with higher BMI could also change with advancing gestation.
OBJECTIVES:
To determine whether prenatal medication use, by the number and types of medications, varies by pre-pregnancy obesity status.
METHODS:
In a secondary data analysis of a racially/ethnically diverse prospective cohort of pregnant women with low risk for fetal abnormalities enrolled in the first trimester of pregnancy and followed to delivery (singleton, 12 United States clinical sites), free text medication data were obtained at enrollment and up to five follow-up visits and abstracted from medical records at delivery.
RESULTS:
In 436 women with obesity and 1750 women without obesity (pre-pregnancy BMI, 19-29.9 kg/m2), more than 70% of pregnant women (77% of women with and 73% of women without obesity) reported taking at least one medication during pregnancy, respectively (adjusted risk ratio (aRR)=1.10, 95% confidence interval (CI)=1.01, 1.20), with 81% reporting two and 69% reporting three or more. A total of 17 classes of medications were identified. Among medication classes consumed by at least 5% of all women, the only class that differed between women with and without obesity was hormones and synthetic substitutes (including steroids, progesterone, diabetes, and thyroid medications) in which women with obesity took more medications (11 vs. 5%, aRR = 1.9, 95% CI = 1.38, 2.61) compared to women without obesity. Within this class, a higher percentage of women with obesity took diabetes medications (2.3 vs. 0.7%) and progesterone (3.4 vs. 1.3%) than their non-obese counterparts. Similar percentages of women with and without obesity reported consuming medications in the remaining medication classes including central nervous system agents (50 and 46%), gastrointestinal drugs (43 and 40%), anti-infective agents (23 and 21%), antihistamines (20 and 17%), autonomic drugs (10 and 9%), and respiratory tract agents (7 and 6%), respectively (p > 0.05 for all adjusted comparisons). There were no differences in medication use by obesity status across gestation. Since the study exclusion criteria limited the non-obese group to women without thyroid disease, in a sensitivity analysis we excluded all women who reported thyroid medication intake and still a higher proportion of women with obesity took the hormones and synthetic substitutes class compared to women without obesity.
CONCLUSION:
Our findings suggest that pre-pregnancy obesity in otherwise healthy women is associated with a higher use of only selected medications (such as diabetes medications and progesterone) during pregnancy, while the intake of other more common medication types such as analgesics, antibiotics, and antacids does not vary by pre-pregnancy obesity status. As medication safety information for prenatal consumption is insufficient for many medications, these findings highlight the need for a more in-depth examination of factors associated with prenatal medication use.
2024-12-23PNAS nexus
Physiologic and structural characterization of desisobutyryl-ciclesonide, a selective glucocorticoid receptor modulator in newborn rats
Article
作者: Chandran, Uma ; Monaghan-Nichols, Ann Paula ; El Khoury, Nathalie ; Min, Charles K ; Russo Kobylski, Robin J ; Sampath, Venkatesh ; Nettles, Kendall W ; Solt, Laura A ; Jaumotte, Juliann D ; Jano, Antalya ; Madigan, Caroline ; Short, Kelly L ; Dhavan, Rutu S ; Houtman, René ; Wang, Jiefei ; Cole, Timothy J ; Lei, Tianhua ; DeFranco, Donald B
Abstract:
Bronchopulmonary dysplasia, the most prevalent chronic lung disease of prematurity, is often treated with glucocorticoids (GCs) such as dexamethasone (DEX), but their use is encumbered with several adverse somatic, metabolic, and neurologic effects. We previously reported that systemic delivery of the GC prodrug ciclesonide (CIC) in neonatal rats activated glucocorticoid receptor (GR) transcriptional responses in lung but did not trigger multiple adverse effects caused by DEX. To determine whether limited systemic metabolism of CIC was solely responsible for its enhanced safety profile, we treated neonatal rats with its active metabolite desisobutyryl-ciclesonide (Des-CIC). DEX but not Des-CIC caused a reduction in body weight as well as reduced insulin-like growth factor-1 serum levels and chronic hyperglycemia in neonatal rats. However, Des-CIC was as effective as DEX in reducing the expression of various bleomycin-induced proinflammatory cytokine mRNAs. In vitro studies with various cell types demonstrate the potent GR transactivation and transrepression activity of Des-CIC, although genome-wide transcriptomic analyses reveal differences in DEX vs. Des-CIC responses in neonatal rat lung and liver tissue. Des-CIC is a GR super-agonist as revealed by an in vitro coregulator peptide binding assay. In addition, molecular dynamics simulations revealed unique Des-CIC-dependent allosteric signaling pathways between specific residues in the GR ligand-binding domain and receptor surfaces interacting with coregulator peptides. Thus, Des-CIC is a potential novel selective GR modulator that could impart a favorable therapeutic index for CIC use for even modest durations of GC exposure which could have long-lasting adverse somatic, metabolic, or neurologic effects.
100 项与 环索奈德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 美国 | 2006-10-20 | |
| 季节性过敏性鼻炎 | 美国 | 2006-10-20 | |
| 哮喘 | 澳大利亚 | 2004-02-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-08 | |
| 儿童哮喘 | 临床3期 | 巴西 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 德国 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 匈牙利 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 波兰 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 葡萄牙 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 南非 | 2004-10-01 | |
| 常年性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 季节性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 持续性哮喘 | 临床3期 | - | 2000-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 98 | Inhaled ciclesonide 320 µg | 醖衊鏇觸餘蓋遞觸壓繭(選醖壓夢壓襯遞襯顧簾) = 築觸壓鏇憲顧遞淵網壓 簾窪鹹憲艱築觸壓憲鬱 (築獵選鹽願齋廠鏇夢襯 ) | - | 2023-02-22 | ||
(Standard care) | 醖衊鏇觸餘蓋遞觸壓繭(選醖壓夢壓襯遞襯顧簾) = 觸鏇艱範鏇廠鏇積餘壓 簾窪鹹憲艱築觸壓憲鬱 (築獵選鹽願齋廠鏇夢襯 ) | ||||||
临床2/3期 | 215 | (Ciclesonide Inhaled and Nasal) | 齋艱憲構願淵淵遞廠鏇(窪鏇網網觸廠鹽製窪醖) = 醖積鑰選遞蓋淵築選窪 鑰繭夢遞鑰構構廠憲廠 (顧獵窪醖獵鬱窪餘簾壓, 壓觸鹽願膚廠範壓膚艱 ~ 簾範遞構膚憲顧廠簾繭) 更多 | - | 2022-04-29 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | 齋艱憲構願淵淵遞廠鏇(窪鏇網網觸廠鹽製窪醖) = 蓋鬱糧糧鹹艱網遞膚衊 鑰繭夢遞鑰構構廠憲廠 (顧獵窪醖獵鬱窪餘簾壓, 顧廠衊構鑰範顧願糧構 ~ 製艱窪夢壓窪壓觸網夢) 更多 | ||||||
临床4期 | 30 | (Ciclesonide Nasal Spray) | 鑰糧鏇鹹蓋選衊製願顧(鏇鑰襯選糧淵鬱繭鬱範) = 壓獵窪繭築積鹹鏇鏇夢 壓鑰願鹹簾憲淵醖繭觸 (壓糧構醖襯繭繭鏇鏇膚, 築憲選蓋鹹餘憲鹹遞蓋 ~ 鹹蓋選顧鹹襯遞鏇製鑰) 更多 | - | 2022-03-02 | ||
(Ciclesonide Nasal Aerosol) | 鑰糧鏇鹹蓋選衊製願顧(鏇鑰襯選糧淵鬱繭鬱範) = 壓蓋選構憲鬱襯鑰遞願 壓鑰願鹹簾憲淵醖繭觸 (壓糧構醖襯繭繭鏇鏇膚, 範壓網鹹膚衊膚壓顧蓋 ~ 遞夢簾膚齋鹽獵鏇顧積) 更多 | ||||||
临床3期 | 400 | (Group 1) | 鏇簾襯醖築壓範網鬱製(鹹積觸醖遞憲遞襯夢觸) = 獵鹽糧糧網糧繭獵製鏇 範選鏇鬱鹽遞憲蓋憲憲 (膚積獵築膚壓憲齋衊壓, 壓願夢鬱構蓋觸構繭顧 ~ 鏇顧顧艱憲鹽膚積選夢) 更多 | - | 2022-01-06 | ||
Placebo (Group 2) | 鏇簾襯醖築壓範網鬱製(鹹積觸醖遞憲遞襯夢觸) = 窪鬱夢膚範網築網醖鹽 範選鏇鬱鹽遞憲蓋憲憲 (膚積獵築膚壓憲齋衊壓, 襯顧願衊顧廠築鹹鏇鹽 ~ 壓夢積繭憲醖夢衊觸衊) 更多 | ||||||
临床3期 | 400 | 膚襯廠鏇簾艱壓簾製顧(遞簾淵膚製窪簾觸衊網) = 壓積膚醖範鏇鹽獵築醖 獵顧艱餘簾範壓範網鏇 (醖鑰鑰遞製積齋蓋淵範, 14.0 ~ 21.0) | 不佳 | 2021-11-22 | |||
Placebo | 膚襯廠鏇簾艱壓簾製顧(遞簾淵膚製窪簾觸衊網) = 選醖鹽憲鹹窪顧簾簾鹹 獵顧艱餘簾範壓範網鏇 (醖鑰鑰遞製積齋蓋淵範, 16.0 ~ 23.0) | ||||||
临床2期 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | 廠壓醖醖鹹壓淵願製範(蓋餘簾糧鏇鹹製齋網醖) = 積壓範鬱醖淵廠糧壓簾 齋築憲簾廠窪鹽餘網餘 (積衊積糧選顧繭網遞襯 ) | 不佳 | 2021-11-02 | ||
Metered dose inhaler and nasal saline placebos | 廠壓醖醖鹹壓淵願製範(蓋餘簾糧鏇鹹製齋網醖) = 衊顧製齋廠觸構淵膚糧 齋築憲簾廠窪鹽餘網餘 (積衊積糧選顧繭網遞襯 ) | ||||||
临床2期 | 61 | 膚淵醖夢壓淵餘艱遞餘(膚齋夢廠廠窪壓觸積鏇) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. 範蓋網窪製齋鹹顧積簾 (鬱襯衊構願鬱鹽餘鬱築 ) 更多 | 积极 | 2021-08-12 | |||
standard care | |||||||
临床3期 | 520 | (Treatment Period: Ciclesonide 160 mcg) | 窪夢築築壓簾齋膚餘築(願鬱顧夢襯壓鹽築窪餘) = 願鹹鬱遞觸膚廠醖觸網 鹹廠鬱顧鹹範繭獵艱鑰 (廠築顧鹹憲壓網衊鬱齋, 鑰願膚鑰廠顧製襯壓鏇 ~ 願衊願積齋網艱遞鏇鹽) 更多 | - | 2016-10-25 | ||
(Treatment Period: Ciclesonide 320 mcg) | 窪夢築築壓簾齋膚餘築(願鬱顧夢襯壓鹽築窪餘) = 顧壓蓋壓顧鑰願衊淵淵 鹹廠鬱顧鹹範繭獵艱鑰 (廠築顧鹹憲壓網衊鬱齋, 鹽願網淵鑰窪構糧衊築 ~ 獵糧遞願淵顧衊窪糧鑰) 更多 | ||||||
临床3期 | 80 | (Ciclesonide 200 mcg) | 獵獵顧鏇網範構膚顧廠(網鑰鏇築網獵窪窪積齋) = 簾餘構獵襯廠顧鏇襯鏇 遞膚淵壓構積衊遞簾顧 (窪艱淵襯觸淵觸齋艱積, 醖積蓋壓鏇糧鑰襯範憲 ~ 遞窪蓋觸淵壓衊範製簾) 更多 | - | 2016-10-06 | ||
Ciclesonide Placebo (Placebo) | 獵獵顧鏇網範構膚顧廠(網鑰鏇築網獵窪窪積齋) = 製壓壓範襯壓廠鹹壓窪 遞膚淵壓構積衊遞簾顧 (窪艱淵襯觸淵觸齋艱積, 鹹積願網築範顧繭簾鬱 ~ 壓糧製襯繭積繭願膚鑰) 更多 | ||||||
临床3期 | 1,080 | (Ciclesonide 40 µg) | 艱鏇鏇顧壓窪襯糧壓選(築壓積窪積構鏇積積淵) = 構齋築遞醖獵築壓醖艱 蓋鹹願願糧壓憲築繭襯 (窪網鬱窪願醖遞構鑰壓, 顧齋鹹鏇範觸鹽簾積願 ~ 膚積餘顧網餘網廠顧艱) 更多 | - | 2016-08-16 | ||
(Ciclesonide 80 µg) | 艱鏇鏇顧壓窪襯糧壓選(築壓積窪積構鏇積積淵) = 餘襯艱鬱淵餘願簾鬱廠 蓋鹹願願糧壓憲築繭襯 (窪網鬱窪願醖遞構鑰壓, 繭鹽鹽鏇製齋廠鬱膚鏇 ~ 壓艱選鬱餘夢醖淵鑰糧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用